Correlation of PSA and survival in metastatic hormone-sensitive prostate cancer treated with rezvilutamide plus ADT in the CHART trial.
Bian X, Gu W, Zhang X, Xie L, Wang S, Shi B, Sun T, Wei S, Weng Z, Xia S, Han B, Xu Z, Xing J, Zhang D, Xu D, Du C, He C, Wang Q, Yang X, Lian J, Wang W, Ye D.
Bian X, et al. Among authors: lian j.
Med. 2024 Oct 16:100520. doi: 10.1016/j.medj.2024.09.009. Online ahead of print.
Med. 2024.
PMID: 39419035